regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…
R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…
Japan Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of Kobe’s significant potential as a cutting-edge R&D hub for both the national and global life science industries. “Alongside promoting translational…
Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…
See our Cookie Privacy Policy Here
